Shanghai Chest Hospital is the first hospital in China specializing in cardiovascular systems, lung, esophagus, trachea and mediastinum.

There are 580 beds in Shanghai chest hospital.

During the past decade, Shanghai chest hospital conducted 203 clinical trials. In the 10-year time frame, 203 clinical trials started and 17 clinical trials were completed, i.e. on average, 8.4% percent of trials that started reached the finish line to date. In the past 5 years, 120 clinical trials started and 9 clinical trials were completed. i.e. 7.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Shanghai chest hospital" #1 sponsor was "Shanghai Chest Hospital" with 56 trials, followed by "Hoffmann-La Roche" with 15 trials sponsored, "Jiayuan Sun" with 9 trials sponsored, "BeiGene" with 7 trials sponsored and "Hutchison Medipharma Limited" with 7 trials sponsored. Other sponsors include 131 different institutions and companies that sponsored additional 93 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Shanghai chest hospital" #1 collaborator was "LinkDoc Technology (Beijing) Co. Ltd." with 10 trials as a collaborator, "Shanghai Chest Hospital" with 9 trials as a collaborator, "Fudan University" with 4 trials as a collaborator, "West China Hospital" with 4 trials as a collaborator and "Air Force Military Medical University, China" with 3 trials as a collaborator. Other collaborators include 109 different institutions and companies that were collaborators in the rest 104 trials.

According to Clinical.Site data, the most researched conditions in "Shanghai chest hospital" are "Lung Cancer" (27 trials), "Non-small Cell Lung Cancer" (19 trials), "NSCLC" (15 trials), "Carcinoma, Non-Small-Cell Lung" (14 trials) and "Non Small Cell Lung Cancer" (13 trials). Many other conditions were trialed in "Shanghai chest hospital" in a lesser frequency.

Most popular intervention types in "Shanghai chest hospital" are "Drug" (141 trials), "Procedure" (34 trials), "Device" (32 trials), "Other" (14 trials) and "Biological" (12 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "Carboplatin" (18 trials), "Cisplatin" (15 trials), "Pemetrexed" (14 trials) and "Atezolizumab" (8 trials). Other intervention names were less common.

The vast majority of trials in "Shanghai chest hospital" are 230 trials for "All" genders.

Currently, there are 108 active trials in "Shanghai chest hospital". 10 are not yet recruiting, 61 are recruiting, 35 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 49 completed trials in Shanghai chest hospital, 1 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Shanghai chest hospital, 30 "Phase 1" clinical trials were conducted, 57 "Phase 2" clinical trials and 65 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 46 trials that are defined as “Not Applicable".